Detailed Narrative
Cyber Incident Impact and Recovery
A cyber incident occurred late in Q1, causing global disruption🌐 to Stryker's business operations, including production shutdowns and revenue recognition delays. The company, in partnership with third-party experts, quickly removed the unauthorized party and brought systems back online by April 1. Management highlighted the successful recovery of 100% of backups, enabling a swift return to operational status across its global manufacturing network.
Segment Reorganization and Reporting Changes
Stryker established a new Ortho Tech business at the beginning of Q1, combining Mako and Enabling Technologies with the Orthopaedic Instruments portfolio to simplify the customer experience and accelerate innovation. Concurrently, Neuro Cranial businesses are now reported together with the remaining Surgical Technologies portfolio under Instruments. These changes align with the company's internal organizational structure and are reflected in updated segment disclosures.
Market Demand and Capital Environment
Despite the operational disruption from the cyber incident, underlying demand across Stryker's businesses remained healthy in Q1. Procedural volumes were solid, supported by favorable demographics and the continued adoption of robotic-assisted surgery. The hospital CapEx environment remains steady, and the company's capital order book is elevated, indicating no slowdown in customer orders.
Mako Momentum and New Indications
Stryker achieved its best-ever Q1 for Mako installations, both domestically and internationally, with high and increasing utilization rates. The Mako 4 system is gaining significant uptake, and Mako Shoulder is anticipated to fully launch on Mako 4 mid-year, receiving positive surgeon feedback. The Mako RPS handheld system is also showing promising early feedback, particularly in ASCs, complementing Mako's existing momentum.
M&A Strategy and Peripheral Vascular Expansion
The company announced an agreement to acquire Amplitude Vascular Systems (AVS), expected to close in Q2. This acquisition aims to expand treatment options for peripheral vascular customers and broaden Stryker's presence in the cardiovascular space. Management emphasized a strong M&A pipeline and significant financial firepower, with a gross debt-to-EBITDA ratio of 2.1, indicating a readiness for further strategic acquisitions.
International Growth and Product Approvals
International markets continue to be a significant growth engine, with Japan performing at a very high level and Europe expected to benefit from the recent approval of Pangea in the latter half of 2026. Other regions like India, East Asia, and Korea are also accelerating. The company is leveraging its innovation and commercial models to capture market share in these geographies, with products like Mako and Fluorescence Imaging gaining traction.
Key Product Launches and Pipeline
Pangea has driven explosive growth in U.S. trauma and recently received European approval, expected to provide a tailwind into 2027-2028. LIFEPAK 35 is approved in Europe and the U.S., with a long product life cycle. The Incompass Total Ankle has launched, but broader adoption is contingent on the upcoming approval of PROPHECY cut guides. The Sonopet 4 ultrasonic aspirator is also slated for launch in the latter part of the year.